title: Effects of intrarenal administration of the cox-2 inhibitor parecoxib during porcine suprarenal aortic cross-clamping.
abstract: The aim of this study was to investigate the effects of intrarenal administration of the cyclooxygenase-2 inhibitor parecoxib during suprarenal aortic cross-clamping. In a prospective, controlled, blinded, randomized manner, 16 anesthetized and mechanically ventilated pigs were instrumented to measure systemic and right kidney hemodynamics, oxygen exchange, and metabolism. During 45 min of suprarenal aortic cross-clamping, animals received 40 mg of parecoxib (n = 8) or vehicle (n = 8) infused continuously into the right renal artery. Hemodynamic and metabolic data, right kidney venous blood, as well as urine samples were obtained before clamping, as well as before and 75 and 195 min after declamping. Clamping transiently increased mean arterial pressure in both groups. Systemic and renal blood flow did not differ between the pre- and postclamping measurements or between groups. Parecoxib attenuated the otherwise significant fall in right kidney creatinine clearance (controls: from 45 [7;111] to 17 [9;22] mL/min; parecoxib: from 39 [3;59] to 27 [11;45] mL/min, P = 0.039 and P = 0.297, respectively versus before clamping, P = 0.021 versus controls at 195 min) and prevented the impairment of renal lactate balance observed in the control group (controls: from 0.5 [-0.8;3.5] to 0.2 [-0.2;0.6] mumol/kg/min; parecoxib: from 0.6 [-1.0;2.0] to 0.4 [-1.2;0.6] mumol/kg/min, P = 0.038 and P = 0.285, respectively, versus before clamping). In conclusion, intrarenal parecoxib infusion beneficially influenced kidney function in this clinically relevant model of suprarenal aortic cross-clamping.
authors.affiliation: Division of Pathophysiology and Process Development in Anesthesia, Department of Pathology, University Hospital, 89075 Ulm, Germany.
authors.forename: Balázs
authors.initials: B
authors.lastname: Hauser
authors.forename: Gebhard
authors.initials: G
authors.lastname: Fröba
authors.forename: Hendrik
authors.initials: H
authors.lastname: Bracht
authors.forename: Jörn
authors.initials: J
authors.lastname: Sträter
authors.forename: Archil B
authors.initials: AB
authors.lastname: Chkhouta
authors.forename: Damian
authors.initials: D
authors.lastname: Vassilev
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Schoaff
authors.forename: Markus
authors.initials: M
authors.lastname: Huber-Lang
authors.forename: Uwe B
authors.initials: UB
authors.lastname: Brückner
authors.forename: Peter
authors.initials: P
authors.lastname: Radermacher
authors.forename: Hubert
authors.initials: H
authors.lastname: Schelzig
mesh_terms: D000792:Angiography; D000818:Animals; D001011:Aorta / Q000473:pathology; D017544:Aortic Aneurysm, Abdominal / Q000601:surgery; D016718:Arachidonic Acid / Q000378:metabolism; D003404:Creatinine / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D005260:Female; D006439:Hemodynamics; D007555:Isoxazoles / Q000008:administration & dosage / Q000494:pharmacology*; D007668:Kidney / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D008297:Male; D011446:Prospective Studies; D012039:Regional Blood Flow; D012079:Renal Circulation / Q000187:drug effects*; D015427:Reperfusion Injury; D013552:Swine; D013997:Time Factors
chemical_list: D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D016718:Arachidonic Acid; C409945:parecoxib; D003404:Creatinine; D051546:Cyclooxygenase 2